Oppenheimer & CO Inc Mereo Biopharma Group PLC Transaction History

Oppenheimer & CO Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	SELL	$0.79 - $1.43 $7,900 - $14,300	-10,000 Reduced 41.67%	14,000 $18,000
Q4 2022 Feb 07, 2023	SELL	$0.5 - $1.01 $1,000 - $2,020	-2,000 Reduced 7.69%	24,000 $18,000
Q2 2022 Aug 08, 2022	BUY	$0.33 - $1.69 $1,980 - $10,140	6,000 Added 30.0%	26,000 $29,000
Q4 2021 Feb 02, 2022	BUY	$1.51 - $2.59 $1,510 - $2,590	1,000 Added 5.26%	20,000 $32,000
Q3 2021 Nov 12, 2021	BUY	$2.2 - $3.17 $41,800 - $60,230	19,000 New	19,000 $46,000

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $419M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.